New drug combo targets head and neck cancer with precision radiation

NCT ID NCT04105543

Completed Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 28 times

Summary

This early-phase study tested an experimental drug, CLR 131, that delivers radiation directly to cancer cells, combined with standard external beam radiation. The goal was to see if this combination is safe and can deliver a high dose of radiation to tumors in people whose head and neck cancer has come back. The study enrolled 12 participants and used imaging to measure how much radiation reached the tumor.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

UW Cancer Center Johnson Creek

Johnson Creek, Wisconsin, 53038, United States
University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792, United States

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER